Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...

By shutting South Africa out of its overseas funding for the roll-out of the revolutionary six-monthly HIV prevention jab which could potentially end Aids, the Trump administration undercuts its own ...

If injectable medication to prevent infection, which has gained favour across Canada, were widely available in B.C., it would ...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ...

Finding the best blue-chip stocks to buy is never a simple task, especially when markets are shifting. Economic uncertainty, changing interest-rate expectations and the rapid evolution of ...

(In the weekly Health Matters newsletter, Ramya Kannan writes about getting to good health, and staying there. You can ...

Gilead is hoping to break ground early next year on its Chess Hatch campus as part of its plans to expand its presence in ...

An updated Canadian guideline on HIV prevention addresses the expanding range of medications available to reduce the risk of ...